- Early trials of a vaccine that targets a specific gene found in tumors, known as KRAS, has proven to be effective in 84% of patients who had pancreatic or colorectal cancers recur after their initial treatment.
- Biotech company Orbis Health Solutions was approved to begin a phase 3 clinical trial of its melanoma vaccine.
- Results from a phase 2 trial found a drug-vaccine combination developed by Merck and Moderna cut the risk of recurrence or death in patients with severe melanomas by 49%.
- A breast cancer vaccine has shown promise in a phase 1 trial spearheaded by researchers at the Seattle-based University of Washington’s Cancer Vaccine Institute and is preparing to move to phase 2.
- A new vaccine, called SurVaxM, that fights the deadliest form of brain cancer, glioblastoma, has shown promise in early trials.
- A small, phase 1 study found promising results for a pancreatic cancer vaccine.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
